【摘要】 目的探讨强肝胶囊联合拉米夫定治疗慢性乙型肝炎肝纤维化的疗效。方法85例患者随机分为两组,中西药组(40例)用强肝胶囊联合拉米夫定,中药组(45例)单用强肝胶囊,两组均治疗6个月。治疗前3个月内和治疗后1个月内分别进行血清肝纤维化指标和肝穿刺病理学检测。结果(1)血清肝纤维化指标:两组治疗后透明质酸、Ⅳ型胶原、层黏蛋白均显著下降(P<0·05)。(2)肝组织学改变:中西药组炎症活动度改善的总有效率为80·0%,肝纤维化改善总有效率为70·0%;中药组分别为57·8%和75·6%,中西药组治疗后炎症活动度改变程度优于中药组(P<0·05),但肝纤维化程度改变两组比较差异无显著性。结论强肝胶囊联合拉米夫定可明显减轻炎症坏死活动性,单纯强肝胶囊也能改善肝纤维化病变。更多还原

【Abstract】 ObjectiveTo study the therapeutic effects of Qianggan Capsule (QC) combined Lamivudine on hepatic fibrosis in patients with chronic hepatitis B. Methods Eighty-five patients were randomly divided into two groups, group A (40 cases) were treated with QC and Lamivudine and group B (45 cases) were treated with QC alone both for 6 months. Hepatic fibrosis related indexes and pathologic examination of liver biopsy were performed within 3 months before treatment and in 1 month after treatment. Results Serum levels of hyaluronic acid, collagen Ⅳ and laminin decreased markedly after treatment in both groups (P<0.05). Hepatic histopathological examination showed that the total effective rate of impovement in activity of inflammation-necrosis and fibrosis was 80.0 and 70.0 in group A, 57.8 and 75.6 in group B, respectively, the combined treatment showed a better effect in improving the activity of inflammation-necrosis than QC alone (P<0.05), but with no significant difference to the latter in improving fibrosis. Conclusion QC combined Lamivudine could markedly reduce the activity of hepatic inflammation-necrosis, QC alone could also improve hepatic fibrosis.更多还原